Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Operating Expenses (2016 - 2025)

Historic Operating Expenses for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $411.0 million.

  • United Therapeutics' Operating Expenses rose 128.14% to $411.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 1070.56%. This contributed to the annual value of $1.5 billion for FY2024, which is 3131.45% up from last year.
  • Per United Therapeutics' latest filing, its Operating Expenses stood at $411.0 million for Q3 2025, which was up 128.14% from $434.1 million recorded in Q2 2025.
  • United Therapeutics' 5-year Operating Expenses high stood at $443.9 million for Q1 2021, and its period low was $173.9 million during Q1 2022.
  • Moreover, its 5-year median value for Operating Expenses was $315.9 million (2022), whereas its average is $315.0 million.
  • As far as peak fluctuations go, United Therapeutics' Operating Expenses surged by 13412.45% in 2021, and later plummeted by 6082.45% in 2022.
  • United Therapeutics' Operating Expenses (Quarter) stood at $245.4 million in 2021, then grew by 28.73% to $315.9 million in 2022, then grew by 12.25% to $354.6 million in 2023, then grew by 6.66% to $378.2 million in 2024, then rose by 8.67% to $411.0 million in 2025.
  • Its Operating Expenses was $411.0 million in Q3 2025, compared to $434.1 million in Q2 2025 and $411.6 million in Q1 2025.